Recent insider selling at Fortive suggests shares may be overpriced. Despite profitability and growth, the history of share sales is concerning. High insider ownership aligns management with shareholders, but lack of insider buying is worrisome.
Fortive's high P/E ratio is justified by its superior earnings outlook. Shareholders' confidence in future earnings and the company's strong growth outlook make a significant share price drop unlikely.
CEO James A. Lico is confident in the company's 2024 outlook, citing a history of mid-single-digit core growth and mid-teens compounded earnings and free cash flow annually since 2019. He also emphasized the company's successful strategy and its impact over time.
Fortive's CEO views the acquisition as a significant stepping-stone for their Precision Technologies segment, hopeful of the synergies it'll bring to customer solutions and financial results. Foresees EA's addition to assist in the growing multi-industry market.
Fortive's projected growth could be factored into its current share price, possibly making it overvalued. Despite promising future growth, current pricing may not provide the best entry point for investors. Analysts suggest limited upside due to pricing alignment, with further exploration advised should prices decrease in light of growth prospects.
Gainers -$ルナイノベーション(LUNA.US)$+8.55% (acquires LIOS Sensing from NKT A/S' NKT Photonics for 20 million in cash; divested Luna Labs for $21 mln) -$クレネ(CLNN.US)$+3.5% (Presents Updated Clinical Data from Phase 2 RESCUE-ALS and REPAIR trials and Preclinical ALS data at 2022 MDA Clinical & Scientific Conference) -$アストラゼネカ(AZN.US)$+2.3% ( AstraZeneca and$メルク(MRK.US)$'s Lynparza (olaparib) has been approved in the ...
$フォーティブ(FTV.US)$Fortive (FTV) with two target raises. Stock currently around $76 Morgan Stanley from $78 to $82 at Equal Weight Credit Suisse from $84 to $87 at Outperform $ヒューレット・パッカード・エンタープライズ(HPE.US)$Hewlett Packard (HPE) target raised by Raymond James from $19 to $20 at Outperform. Stock currently around $14.50 $ハーシー(HSY.US)$The Hershey (HSY) with a host of target raises. Average price target $200 at Overweight. Stock currently around $175
フォーティブに関するコメント
コラムUS Top Gap Ups and Downs on 4/12: MDB, NET, JD, AAL and More
Gap Ups
1. $National Instruments(NATI.US)$ - up 8.7%
2. $モンゴDB(MDB.US)$ - up 3.1%
3. $チャート・インダストリーズ(GTLS.US)$ - up 2.9%
4. $コンフルーエント(CFLT.US)$ - up 1.9%
5. $ドクター・レディース・ラボラトリーズ(RDY.US)$ - up 1.6%
6. $コサン SA(CSAN.US)$ - up 1.6%
7. $フォーティブ(FTV.US)$ - up 1.5%
8. $クラウドフレア(NET.US)$ - up 1.4%...
コラムTop upgrades and downgrades on 3/17
• $アスペンテクノロジーインク(AZPN.US)$ : Loop Capital Upgrades to Buy from Hold - PT $175
• $CSX(CSX.US)$ : RBC Capital Upgrades to Outperform from Sector Perform - PT $39 (from $37)
• $エコラボ(ECL.US)$ : Edward Jones Upgrades to Buy from Hold
• $フォーティブ(FTV.US)$ : Argus Upgrades to Buy from Hold - PT $68
• $ヘルス・カタリスト(HCAT.US)$ : Jefferies Upgrades To Buy From Hold - PT $28 (From $31)
• $ハンティントン・インガルス・インダストリーズ(HII.US)$ : Vertical Research Upgra...
コラムToday's pre-market stock movers: AZN, NVS, NKLA, CVX and more
- $ルナイノベーション(LUNA.US)$ +8.55% (acquires LIOS Sensing from NKT A/S' NKT Photonics for 20 million in cash; divested Luna Labs for $21 mln)
- $クレネ(CLNN.US)$ +3.5% (Presents Updated Clinical Data from Phase 2 RESCUE-ALS and REPAIR trials and Preclinical ALS data at 2022 MDA Clinical & Scientific Conference)
- $アストラゼネカ(AZN.US)$ +2.3% ( AstraZeneca and $メルク(MRK.US)$ 's Lynparza (olaparib) has been approved in the ...
コラムTop upgrades and downgrades on 3/14
• $BRPグループ(BRP.US)$ : BofA Securities Upgrades to Buy from Neutral - PT $31
• $Centennial Resource Development(CDEV.US)$ : Wells Fargo Upgrades to Equal Weight from Underweight - PT $12 (from $8)
• $エノバ・インターナショナル(ENVA.US)$ : Janney Upgrades to Buy from Neutral - PT $49
• $フォーティブ(FTV.US)$ : Barclays Upgrades to Overweight from Equalweight - PT $75
• $ヘリオス・テクノロジーズ(HLIO.US)$ : KeyBanc Upgrades to Overweight from Sector Weight - PT $90
• $ヘルメリッチ・アンド・ペイン(HP.US)$ : Seaport...
Morgan Stanley from $78 to $82 at Equal Weight
Credit Suisse from $84 to $87 at Outperform
$ヒューレット・パッカード・エンタープライズ(HPE.US)$ Hewlett Packard (HPE) target raised by Raymond James from $19 to $20 at Outperform. Stock currently around $14.50
$ハーシー(HSY.US)$ The Hershey (HSY) with a host of target raises. Average price target $200 at Overweight. Stock currently around $175
まだコメントはありません